Milacemide

• CAT Number: I032279
• CAS Number: 76990-56-2
• Molecular Formula: C7H16N2O
• Molecular Weight: 144.22
• Purity: 98%
• Synonyms: Milacemide; CP1552 S; CP-1552 S; CP 1552 S
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: Acetamide, 2-(pentylamino)-
• InChI: InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10)
• InChIKey: GJNNXIYZWIZFRH-UHFFFAOYSA-N
• SMILES: O=C(N)CNCCCCC

Milacemide is an MAO-B inhibitor and glycine prodrug. It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.

Reference

1.Milacemide, a glycine pro-drug, inhibits strychnine-allodynia without affecting normal nociception in the rat.
Khandwala H, Loomis CW.
Pain. 1998 Jul;77(1):87-95. doi: 10.1016/S0304-3959(98)00086-4.
PMID: 9755023
2.Milacemide enhances memory storage and alleviates spontaneous forgetting in mice.
Quartermain D, Nuygen T, Sheu J, Herting RL.
Pharmacol Biochem Behav. 1991 May;39(1):31-5. doi: 10.1016/0091-3057(91)90393-g.
PMID: 1833781
3.Microionophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells.
Godfraind JM.
Br J Pharmacol. 1990 May;100(1):119-25. doi: 10.1111/j.1476-5381.1990.tb12062.x.
PMID: 2196964 Free PMC article.
4.Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.
Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, Skare S, Fakouhi JD, Herting RL.
J Am Geriatr Soc. 1992 May;40(5):503-6. doi: 10.1111/j.1532-5415.1992.tb02019.x.
PMID: 1634705 Clinical Trial.
5.Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia.
Herting RL.
Ann N Y Acad Sci. 1991;640:237-40. doi: 10.1111/j.1749-6632.1991.tb00225.x.
PMID: 1837978 Clinical Trial.
6.The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B.
Janssens de Varebeke P, Pauwels G, Buyse C, David-Remacle M, De Mey J, Roba J, Youdim MB.
J Neurochem. 1989 Oct;53(4):1109-16. doi: 10.1111/j.1471-4159.1989.tb07403.x.
PMID: 2769256
7.Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B.
Janssens de Varebeke P, Cavalier R, David-Remacle M, Youdim MB.
J Neurochem. 1988 Apr;50(4):1011-6. doi: 10.1111/j.1471-4159.1988.tb10566.x.
PMID: 3346666
8.Cognitive effects of milacemide and methylphenidate in healthy young adults.
Camp-Bruno JA, Herting RL.
Psychopharmacology (Berl). 1994 Jun;115(1-2):46-52. doi: 10.1007/BF02244750.
PMID: 7862911 Clinical Trial.
9.Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?
O’Brien EM, Tipton KF, Strolin Benedetti M, Bonsignori A, Marrari P, Dostert P.
Biochem Pharmacol. 1991 Jun 1;41(11):1731-7. doi: 10.1016/0006-2952(91)90177-7.
PMID: 2043162
10.Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B.
O’Brien EM, Dostert P, Tipton KF.
Biochem Pharmacol. 1995 Jul 31;50(3):317-24. doi: 10.1016/0006-2952(95)00145-p.
PMID: 7646533